Evidence map›Paper›PMID 34985256›Full record

ArticleACS infectious diseases2022

Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.

Lori A Emert-Sedlak, Omar Moukha-Chafiq, Haibin Shi, Shoucheng Du, John J Alvarado, Vibha Pathak, Samuel G Tanner, Robert N Hunter, Miranda Nebane, Li Chen and 9 more

Open access · greenAbstract read
In one paragraph

Article in ACS infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. A high-throughput response to the SARS-CoV-2 pandemic.SLAS discovery : advancing life sciences R & D · 2024
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Lori A Emert-SedlakDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.
Omar Moukha-Chafiq
Haibin ShiDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.
Shoucheng DuDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.
John J AlvaradoDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.
Vibha Pathak
Samuel G Tanner
Robert N Hunter
Miranda Nebane
Li ChenDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.
Tatiana V IlinaDepartment of Structural Biology, School of Medicine, University of Pittsburgh, 3501 Fifth Avenue, Pittsburgh, Pennsylvania 15260, United States.ORCID 0000-0002-9985-5978
Rieko IshimaDepartment of Structural Biology, School of Medicine, University of Pittsburgh, 3501 Fifth Avenue, Pittsburgh, Pennsylvania 15260, United States.
Sixue Zhang
Yury V KuzmichevDepartment of Infectious Disease Research, Drug Development Division, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, United States.
Elizabeth R WonderlichDepartment of Infectious Disease Research, Drug Development Division, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, United States.
Susan M SchaderDepartment of Infectious Disease Research, Drug Development Division, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, United States.
Corinne E Augelli-SzafranORCID 0000-0002-7676-6120
Roger G PtakDepartment of Infectious Disease Research, Drug Development Division, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, United States.
Thomas E SmithgallDepartment of Microbiology and Molecular Genetics, School of Medicine, University of Pittsburgh, 450 Technology Drive, Pittsburgh, Pennsylvania 15219, United States.ORCID 0000-0001-5238-3806
Southern Research Institute · USUniversity of Pittsburgh · US

Funding

Small Molecule Inhibitors of HIV Nef SignalingR01AI057083 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SMITHGALL, THOMAS E. · 2003 to 2019
$5.1M
Chemical Biology of HIV-1 NefR01AI152677 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Thomas E. Smithgall · 2020 to 2026
$4.8M
NIAID NIH HHS HHSN272200700042CNIAID NIH HHS HHSN272201400010CNIAID NIH HHS R01 AI057083NIAID NIH HHS R01 AI152677
6 · The paper itself

Abstract

HIV-1 Nef is an attractive target for antiretroviral drug discovery because of its role in promoting HIV-1 infectivity, replication, and host immune system avoidance. Here, we applied a screening strategy in which recombinant HIV-1 Nef protein was coupled to activation of the Src-family tyrosine kinase Hck, which enhances the HIV-1 life cycle in macrophages. Nef stimulates recombinant Hck activity

Indexed as

HIV-1Down-RegulationMacrophagessrc-Family KinasesVirus Replicationsrc-Family Kinasesantiretroviralshigh throughput screeningHIV-1HIV-1 Nefimmune escapeMHC-I

Identifiers

PMID34985256
PMCPMC9274903
OpenAlexW4205483772

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.